Esperion Therapeutis.Inc. buy StockNews.com
Summary
This prediction ended on 06.10.25 with a price of €2.80. With a performance of 41.81% the BUY prediction by StockNews_com was a big success. StockNews_com has a follow-up prediction for Esperion Therapeutis.Inc. where he still thinks Esperion Therapeutis.Inc. is a Buy. StockNews_com has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Esperion Therapeutis.Inc. | 1.376% | 1.376% | 32.534% |
| iShares Core DAX® | -1.764% | 2.259% | 15.213% |
| iShares Nasdaq 100 | -1.632% | -0.193% | 3.293% |
| iShares Nikkei 225® | -2.451% | 4.086% | 17.198% |
| iShares S&P 500 | -2.252% | -0.151% | 0.574% |
Comments by StockNews_com for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
In the thread Trading Esperion Therapeutis.Inc.
Current prediction by StockNews_com for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
17.08.25
17.08.26
23.01.26
Stopped prediction by StockNews_com for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
26.10.24
26.10.25
27.10.25

